Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Norgestimate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR known ✓ | P06401 | 7/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 4/20 | 1.00 |
| ▸ | NR3C1 | P04150 | 3/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 3/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 2/20 | 1.00 |
| ▸ | AGTR1 | P30556 | 1/20 | 1.00 |
| ▸ | DRD3 | P35462 | 1/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 1.00 |
| ▸ | PDE4D | Q08499 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.58 |
| ▸ | AR | P10275 | 6/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.58 |
| ▸ | MEN1 | O00255 | 3/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.58 |
| ▸ | ABCB11 | O95342 | 3/20 | 0.58 |
| ▸ | MAPT | P10636 | 2/20 | 0.58 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.58 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Norgestimate SCHEMBL15233395 | 1.00 | PGR (1.00) | PGRSLC6A4NR3C1ADORA3SLC6A2 | |
| Norgestimate SCHEMBL38317 | 1.00 | PGR (1.00) | PGRSLC6A4NR3C1ADORA3SLC6A2 | |
| Norgestimate SCHEMBL5173707 | 1.00 | PGR (1.00) | PGRSLC6A4NR3C1ADORA3SLC6A2 | |
| Norgestimate SCHEMBL633395 | 1.00 | PGR (1.00) | PGRSLC6A4NR3C1ADORA3SLC6A2 | |
| Norgestimate SCHEMBL5523236 | 1.00 | PGR (1.00) | PGRSLC6A4NR3C1ADORA3SLC6A2 | |
| Norgestimate SCHEMBL38318 | 1.00 | PGR (1.00) | PGRSLC6A4NR3C1ADORA3SLC6A2 | |
| Norgestimate SCHEMBL28685734 | 0.99 | PGR (0.98) | PGRSLC6A4NR3C1ADORA3SLC6A2 | |
| Norgestimate SCHEMBL7532415 | 0.91 | PGR (0.84) | PGRSLC6A4NR3C1ADORA3SLC6A2 | |
| SCHEMBL24574056 | 0.91 | PGR (0.84) | PGRSLC6A4NR3C1ADORA3SLC6A2 | |
| SCHEMBL11699972 | 0.89 | PGR (0.80) | PGRSLC6A4NR3C1ADORA3SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2116249-B2 | Pharmaceutical compound containing gestagens and/or oestrogens and 5-methyl-(6S)-tetrahydrofolates | BAYER IP GMBH (DE) | 2023-04-05 | — | — | EP | claimed |
| US-10463666-B2 | Pharmaceutical composition comprising progestogens and/or estrogens and 5-methyl-(6S)-tetrahydrofolate | Merck & Cie (CH) | 2019-11-05 | — | — | US | claimed |
| US-20160095860-A1 | Pharmaceutical Composition Comprising Progestogens and/or Estrogens and 5-Methyl-(6S)-tetrahydrofolate | Merck & Cie (CH) | 2016-04-07 | — | — | US | claimed |
| WO-2012055840-A1 | COMPOSITION AND PREPARATION FOR TREATMENT OF DYSMENORRHEA AND MENSTRUAL PAIN AND USE OF A HORMONAL AGENT AND A ZINC SALT FOR TREATMENT OF MENSTRUAL DISORDERS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-05-03 | — | — | WO | claimed |
| EP-2116249-B1 | Pharmaceutical compound containing gestagens and/or oestrogens and 5-methyl-(6S)-tetrahydrofolates | Bayer Pharma AG (DE) | 2012-05-02 | — | — | EP | claimed |
| EP-1888077-B1 | PHARMACEUTICAL COMPOSITION CONTAINING GESTAGENS AND/OR ESTROGENS AND 5-METHYL-(6S)-TETRAHYDROFOLATE | BAYER SCHERING PHARMA AG (DE) | 2009-04-29 | — | — | EP | claimed |
| US-20080160004-A1 | PHARMACEUTICAL COMPOSITION COMPRISING PROGESTOGENS AND/OR ESTROGENS AND 5-METHYL-(6S)-TETRAHYDROFOLATE | MERCK & CIE KG (CH) | 2008-07-03 | — | — | US | claimed |
| US-20060293295-A1 | Pharmaceutical composition comprising progestogens and/or estrogens and 5-methyl- (6S)-tetrahydrofolate | MERCK & CIE KG (CH) | 2006-12-28 | — | — | US | claimed |
| US-20050032763-A1 | Process for the synthesis of high purity D-(17a)-13-ethyl-17-hydroxy-18,19-dinorpregn-4-ene-20-yn-3-one oxime | RICHTER GEDEON VEGYESZETI GYAR RT. (HU) | 2005-02-10 | — | — | US | claimed |
| EP-0904086-B1 | TRANSDERMAL SYSTEMS CONTAINING TWO ACTIVE PRINCIPLES IN SEPARATE COMPARTMENTS, THEIR METHOD OF PREPARATION AND APPLICATION AS MEDICINE | AVENTIS PHARMA SA (FR) | 2004-12-08 | — | — | EP | claimed |
| EP-0500793-B1 | OSMOTIC, ORAL DOSAGE FORM FOR FERTILITY CONTROL | ALZA CORP (US) | 1993-11-03 | — | — | EP | claimed |
| EP-0472645-B1 | OSMOTIC DOSAGE FORM | ALZA CORPORATION (US) | 1993-07-14 | — | — | EP | claimed |
| US-11896602-B2 | Method for preventing pregnancy | ESTETRA SRL (BE) | 2024-02-13 | — | — | US | disclosed |
| WO-2023174947-A1 | ESTETROL FOR USE IN RE-ENDOTHELIALIZATION | ESTETRA SRL (BE) | 2023-09-21 | — | — | WO | disclosed |
| US-11666585-B2 | Compounds and their uses for alleviating menopause-associated symptoms | ESTETRA SRL (BE) | 2023-06-06 | — | — | US | disclosed |
| WO-2023094689-A1 | COMPOSITIONS FOR PREVENTING OR TREATING SKIN AGING | ESTETRA SRL (BE) | 2023-06-01 | — | — | WO | disclosed |
| EP-0904086-B1 | TRANSDERMAL SYSTEMS CONTAINING TWO ACTIVE PRINCIPLES IN SEPARATE COMPARTMENTS, THEIR METHOD OF PREPARATION AND APPLICATION AS MEDICINE | AVENTIS PHARMA SA (FR) | 2004-12-08 | — | — | EP | disclosed |
| EP-0904086-A1 | TRANSDERMAL SYSTEMS CONTAINING TWO ACTIVE PRINCIPLES IN SEPARATE COMPARTMENTS, THEIR METHOD OF PREPARATION AND APPLICATION AS MEDICINE | HOECHST MARION ROUSSEL (FR) | 1999-03-31 | — | — | EP | disclosed |
| WO-1997047305-A1 | TRANSDERMAL SYSTEMS CONTAINING TWO ACTIVE PRINCIPLES IN SEPARATE COMPARTMENTS, THEIR METHOD OF PREPARATION AND APPLICATION AS MEDICINE | HOECHST MARION ROUSSEL (FR) | 1997-12-18 | — | — | WO | disclosed |
| US-4027019-A | 3-Oximes of D-17α-ethynyl-19-nortestosterone esters and method | ORTHO PHARMACEUTICAL CORPORATION (US) | 1977-05-31 | — | — | US | disclosed |